tbuckley/cabot-search huggingface dataset:
A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies
Authors: Veerendra Munugalavadla, Leanne Berry, Yung-Hsiang Chen, Gauri Deshmukh, Jake Drummond, Changchun Du, Michael Eby, Karen Fitzgerald, Lori S. Friedman, Stephen E. Gould, Jane R. Kenny, Heather Maecker, John Moffat, Marina Moskalenko, Patricia Pacheco, Alham Saadat, Dion Slaga, Laura Sun, Gina Wang, Yagai Yang, Allen J. Ebens
Journal: Blood (2010)
Comparison of 6586 Unrelated Bone Marrow Transplants (UBMT) and 2713 Unrelated Cord Blood Transplants (UCBT) in Japan.
Authors: Shunichi Kato, Yasuo Morishima, Yoshiko Atsuta, Tokiko Nagamura, Yoichiro Takaue, Hisashi Sakamaki, Shinichiro Okamoto, Satoshi Takahashi, Shuichi Taniguchi, Koji Kato, Keiichi Isoyama, Minoko Takanashi, Shunro Kai, Hiroshi Azuma, Masahiro Tsuchida, Keisei Kawa, Yoshihisa Kodera
Journal: Blood (2007)
OC-042 Benefits of Service Redesign with a Tertiary Symptomatic Colorectal EMR Service Managed within Bowel Cancer Screening Service Model: Abstract OC-042 Table 1
Authors: G Keeley, HL Gibson, P O’Toole, M Mbuyongha, G Fitzgerald, D Gould, S Sarkar
Journal: Gut (2016)

<h3>Introduction</h3> One of the high quality service developments in endoscopy in the UK has been the introduction of the Bowel Cancer Screening Programme due to the rigorous quality assurance not just of the colonoscopy but of all aspects of the patient journey. Whilst the Royal Liverpool is a tertiary referral site for colorectal complex polyp/Endoscopic Mucosal Resection for BCSP and the symptomatic service for the North-West, the patient journey and quality of service varied significantly depending whether they were referred through via the BCSP or the symptomatic route. <h3>Methods</h3> We modelled the patient pathway within the symptomatic service to the BCSP standard of care. We seconded two SSPs and BCSP admin to work 50% with the EMR service and 50% within BCSP. All referrals were initially reviewed by EMR specialist endoscopists and then handed to the SSPs to be entered onto a bespoke database. Telephone assessment of patients was performed by an SSP who actively managed the patients co-morbidities and charted them on the database. Patients were listed onto dedicated EMR lists with adequate slot allocations as determined by the EMR endoscopist. Post procedure, patients had a follow-up phone call and their histology and post discharge follow up was monitored and managed by the team including MDT handover in the referral centres. <h3>Results</h3> Since the start of the service (24<sup>th</sup> August 2015) 138 patients have been managed through the service. The mean age was 77 years. Referral pathways have included:51% external tertiary referrals, 6% from MDT and 43% internal tertiary referrals. 31 telephone assessments have been performed. In 25% patients a successful intervention by the team resulted in a positive outcome. These included interventions in; Pre-procedure work up &amp; management of co-morbidities (n = 14), administration (n = 12), post-procedure complications (n = 5) and change in management following histology results (n = 3). See Table for full details <h3>Conclusion</h3> Re-design of the symptomatic EMR service using the expertise within our BCSP with similar principles in pathway management has had a significant impact on patient safety and outcomes within this service. <h3>Disclosure of Interest</h3> None Declared
Validation and development of MTH1 inhibitors for treatment of cancer
Authors: U. Warpman Berglund, K. Sanjiv, H. Gad, C. Kalderén, T. Koolmeister, T. Pham, C. Gokturk, R. Jafari, G. Maddalo, B. Seashore-Ludlow, A. Chernobrovkin, A. Manoilov, I.S. Pateras, A. Rasti, A.-S. Jemth, I. Almlöf, O. Loseva, T. Visnes, B.O. Einarsdottir, F.Z. Gaugaz, A. Saleh, B. Platzack, O.A. Wallner, K.S.A. Vallin, M. Henriksson, P. Wakchaure, S. Borhade, P. Herr, Y. Kallberg, P. Baranczewski, E.J. Homan, E. Wiita, V. Nagpal, T. Meijer, N. Schipper, S.G. Rudd, L. Bräutigam, A. Lindqvist, A. Filppula, T.-C. Lee, P. Artursson, J.A. Nilsson, V.G. Gorgoulis, J. Lehtiö, R.A. Zubarev, M. Scobie, T. Helleday
Journal: Annals of Oncology (2016)
AB0690 Profile of Juvenile-Onset Compared To Adult-Onset Spondyloarthritis
Authors: J. Essouiri, F. Awassi, F.E. Abourazzak, T. Harzy
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> the aim of our study is to analyze the differences and similarities between a group of juvenile-onset spondyloarthritis (JOSpA) (≤16 years) and a group of adult-onset spondyloarthritis (&gt;16 years) (AOSpA). <h3>Methods</h3> This is a retrospective observational study, conducted in the rheumatology department at CHU Hassan II Fez, analyzing the records of patients diagnosed spondyloarthritis during the period extending from January 2009 to June 2014. We realized a descriptive study of our patients (clinical and epidemiological parameters) then we compared JOSpA and AOSpA to emphasize the characteristics of juvenile onset spondyloarthritis. <h3>Results</h3> A 84 patients were included 22 with JOSpA and 62 with AOSpA. The mean age was 30,90±10,5 years with the average diagnosis delay of 5,68±5,74 years. Diagnosis according to ASAS criteria was in 73,8% of cases, according to AMOR criteria in 21,4% of cases and 4,8% according to NYM criteria. Clinical symptomatology was dominated by axial involvement dorsolombalgie in 89,3%. Uveitis was the extra-articular manifestation most common in 8,3%. The average Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was 4,62±1,907, the average Bath Ankylosing Spondylitis Functional Index (BASFI) was 4,56±2,485. 34.5% patients had a hip involvement. The variables associated with JOSpA were lower limb arthritis (p=0.04), hip involvement (p=0,001), enthesitis chest pain (p=0,04) and the use of anti TNF alpha (p=0,008). After logistic regression analysis the JOSpA was associated with enthesitis chest pain (p=0,011; OR=8,2, IC=1,62–41,34) and the use of anti TNF alpha (p=0,001; OR=9,1; IC=2,39–34,69) <h3>Conclusions</h3> Our study showed that JOSpA is associated with enthesitis and the use of anti TNF alpha. This characterization will help to understand the characteristics of the JOSpA patients and their needs in the long-term follow up. <h3>Disclosure of Interest</h3> None declared
AB1002 Determinants of Quality of Life, Labor-Market Status and Healthcare Utilization in Ankylosing Spondylitis Patients
Authors: F.M. Pimentel-Santos, I. Peyroteo, A.F. Mourão, E. Sousa, J. Costa, H. Santos, A. Barcelos, P. Pinto, J.E. Fonseca, J.C. Branco, P.P. Barros
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ankylosing Spondylitis (AS) typically affects young people, leading to progressive deterioration of physical function and quality of life (QoL) with higher use of healthcare services. Work disability and early retirement is also higher in AS patients than in the general population, with a remarkable negative impact on productivity and social costs. <h3>Objectives</h3> The objectives of this study were to assess the gradient of AS severity, measured by several well-established scores, for QoL, labour-market status and healthcare services demand, in a group of AS patients. <h3>Methods</h3> We collected cross-sectional data in patients under 65 years, concerning demographic characteristics, disease duration, time to diagnosis, BASDAI, BASFI, BASMI, SF-36, ASQoL, EQ-5D and evaluated the ASDAS. The number of appointments and emergency room visits during the year before and working status in active ages people, were also collected. To measure the gradient of AS on QoL scores, healthcare use and working status, regression models, with application of stepwise procedure for removal of statistically non-significant effects, were performed. <h3>Results</h3> A total of 369 patients were included (62.3% men and 37.1% women), with a mean age of 45.4±13.2 years (range 20–79 years). For SF-36 and ASQoL, only BASDAI and BASFI scores matter and both mean higher value associated with lower health and it seems that a one point increase in one score is roughly equal to one point increase in the other score. The same conclusion holds for EQ5D. The only difference lies with the group of patients with 7–12 years of schooling, who have higher utility score than the others. The probability of being employed is negatively related to age and to BASMI. Only the BASFI is positively associated with the number of medical appointments. Age and ASDAS are the only determinants of emergency rooms visits. <h3>Conclusions</h3> BASDAI and BASFAI, which are modifiable scores, are negatively associated with utility/ QoL scores. Age and BASMI (no modifiable scores) are negatively associated with being employed. In addition, earlier or later disease detection, have no influence on these gradients. Accuracy of therapy intervention has a pivotal role on impacts, more than a precise time in detection. <h3>Disclosure of Interest</h3> None declared
Prognostic Factors on Survival After Hematopoietic Stem Cell Transplantation for Adult Over 40 Years In Aplastic Anemia.
Authors: Hawk Kim, Jae-Yong Kwak, Byung Soo Kim, Sung Hyun Kim, Sung-Hwa Bae, Sang Kyun Sohn, Ho-Jin Shin, Jong-Ho Won, Sung-Soo Yoon, Deog-Yeon Jo, Young-Don Joo, Jung Hye Choi, Myung Soo Hyun, Kyoo Hyung Lee
Journal: Blood (2010)
The Therapeutic Effect of Umbilical Mesenchymal Stem Cells Injected Directly Into Medullary Cavity of Ilium to Treat Refractory Aplastic Anemia and Bone Marrow Fibrosis,
Authors: Zhuanzhen Zheng, Zhenhua Qiao, Wenliang Chen, Rong Gong, Yalin Wang, Lianrong Xu, Yanping Ma, Lihong Hou, Li Zhang, Yujin Lu, Bo Jiang, Guoxia Li, Chunxia Dong
Journal: Blood (2011)
Sequential Enzymatic Down-Regulation and Degradation of the Lyn Tyrosine Kinase in Erythropoietin-Stimulated Cells.
Authors: Evan Ingley, Jessica R. Schneider, David J. McCarthy, Kenneth W. Harder, Margaret L. Hibbs, Warren S. Alexander, Douglas J. Hilton, Svend Peter Klinken
Journal: Blood (2004)
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
Authors: Thomas R. Flint, Tobias Janowitz, Claire M. Connell, Edward W. Roberts, Alice E. Denton, Anthony P. Coll, Duncan I. Jodrell, Douglas T. Fearon
Journal: Cell Metabolism (2016)

In patients with cancer, the wasting syndrome, cachexia, is associated with caloric deficiency. Here, we describe tumor-induced alterations of the host metabolic response to caloric deficiency that cause intratumoral immune suppression. In pre-cachectic mice with transplanted colorectal cancer or autochthonous pancreatic ductal adenocarcinoma (PDA), we find that IL-6 reduces the hepatic ketogenic potential through suppression of PPARalpha, the transcriptional master regulator of ketogenesis. When these mice are challenged with caloric deficiency, the resulting relative hypoketonemia triggers a marked rise in glucocorticoid levels. Multiple intratumoral immune pathways are suppressed by this hormonal stress response. Moreover, administering corticosterone to elevate plasma corticosterone to a level that is lower than that occurring in cachectic mice abolishes the response of mouse PDA to an immunotherapy that has advanced to clinical trials. Therefore, tumor-induced IL-6 impairs the ketogenic response to reduced caloric intake, resulting in a systemic metabolic stress response that blocks anti-cancer immunotherapy.
Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.
Authors: Martin S. Tallman, Haesook T. Kim, Charles A. Schiffer, Frederick R. Appelbaum, James H. Feusner, Angela K. Ogden, Lois Shepherd, Cheryl L. Willman, Clara D. Bloomfield, Jacob M. Rowe, Richard A. Larson, Peter H. Wiernik, Guillermo Martin, Chelo Rayon, Javier de la Serna, Concha Rivas, Jose D. Gonzalez-San Miguel, Guillermo Deben, Miguel A. Sanz
Journal: Blood (2004)
CXCR4 as a Predictor of Response in Acute Myeloid Leukemia
Authors: Domenico Pastore, Anna Mestice, Margherita Giannoccaro, Arcangelo Liso, Maria Paola Martelli, Paola Carluccio, Francesco Albano, Mario Delia, Antonella Russo Rossi, Manuela Leo, Alessandra Pannunzio, Vincenzo Liso, Brunangelo Falini, Giorgina Specchia
Journal: Blood (2008)
p38 MAPK Controls Sensitivity Towards BH3 Mimetics By Regulating Mcl-1 Expression of Chronic Lymphocytic Leukemia in Hypoxia and Acquired Resistance
Authors: Malte F Huelsemann, Michaela Patz, Laura Beckmann, Kerstin Brinkmann, Teresa Otto, Joachim Fandrey, Hans Jiro Becker, Sebastian Theurich, Michael S. von Bergwelt-Baildon, Christian P. Pallasch, Réne P. Zahedi, Hamid Kashkar, Christian Reinhardt, Michael Hallek, Clemens-Martin Wendtner, Lukas P. Frenzel
Journal: Blood (2014)
Abstract 20813: Improved Coronary Microvascular Function in Overweight Patients With Coronary Artery Disease Obtained After 12 Weeks of Aerobic Interval Training or Low Energy Diet is Not Maintained After 1 Year: Results From the Randomized Trial Cut-It
Authors: Rasmus Huan Olsen, Lene Rørholm Pedersen, Martin Snoer, Steen B Haugaard, Eva Prescott
Journal: Circulation (2016)

Introduction: Impaired coronary microvascular function in terms of low coronary flow velocity reserve (CFVR) carries a poor prognosis and is prevalent in coronary artery disease (CAD) and obesity. CFVR can be improved in overweight and obese patients by aerobic interval training (AIT) or weight loss by low energy diet (LED), however, lifestyle changes and attained benefits are difficult to sustain. We examined whether improved coronary microvascular function measured as CFVR could be maintained one year after initiating AIT or LED.

Methods: Seventy, non-diabetic, stable and revascularized CAD patients with BMI 28-40 kg/m2 and age 45-75 years were randomized (1:1) to 1) 12 weeks’ AIT (16 min at 90% of peak heart rate) three times/week followed by 40 weeks’ AIT twice weekly or 2) an LED (800-1000 kcal/day) for 8-10 weeks followed by a weight maintenance diet and AIT twice weekly. CFVR was the primary outcome and assessed by transthoracic echocardiography as the ratio between pulsed wave Doppler measured coronary flow velocity of the LAD during adenosine induced myocardial hyperemia and rest. Aerobic exercise capacity (VO2peak) was measured by indirect-calorimetry and corrected for dual-energy X-ray absorptiometry (DEXA) estimated fat free body mass (FFM). Statistical analyses were performed using mixed-model ANOVA with repeated measurements.

Results: Twenty-six (74%) AIT and 25 (71%) LED+AIT participants completed the one-year intervention with valid CFVR measurements. Forty-one (80%) were male, mean age 63 (6.4) years, median BMI 31.3 kg/m2 (inter-quartile-range 29.6-33.5) and VO2peak 20.7 (4.9) mL/kg. Effects on body weight and body composition, VO2peak and CFVR are given in the table.

Conclusion: Despite improved body composition and significant weight loss, the improvements in coronary microvascular function obtained after 12 weeks of intervention were not maintained to the one-year follow-up.

   ![][1]  [1]: /embed/graphic-1.gif
FRI0517 The Omeract Ultrasonographic Criteria for Elementary Lesions in Calcium Pyrophosphate Deposition Disease: Results of A Delphi Process by Ultrasound Working Group
Authors: A. Adinolfi, G. Filippou, C.A. Scirè, N. Damjanov, G. Carrara, V. Picerno, C. Toscano, G. Bruyn, M.A. D'Agostino, A. Delle Sedie, E. Filippucci, M. Gutierrez, M. Micu, I. Moller, E. Naredo, Z. Pascal, C. Pineda, F. Porta, W. Schmidt, L. Terslev, V. Vlad, P. Zufferey, B. Frediani, A. Iagnocco
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In the last years, the role of Ultrasound (US) for the diagnosis of calcium pyrophosphate deposition disease (CPPD) has been extensively growing. However, some issues have still to be resolved, being one of the most important the heterogeneity of the criteria used for the identification of calcium pyrophosphate crystals (CPP) deposits. <h3>Objectives</h3> The aim of this study was to define the US elementary lesions in CPPD <h3>Methods</h3> The panel of experts was compound by 18 members of the Omeract US group, especially interested in microcrystalline arthritides. The first step was a systematic literature review aimed to select the studies regarding US and CPPD in order to collect all the definitions about US elementary findings in CPPD. The definitions retrieved by the literature were used for drawing up a first group of propositions. The experts evaluated these definitions, adding any further preposition according to their experience that could improve the initial set. According to the systematic review, the propositions about US elementary lesions were divided by anatomical structure: fibrocartilage, hyaline cartilage, tendons and synovial fluid. For each structure were defined: shape, echogenicity, localization and behaviour at dynamic scanning. In the next rounds, the experts voted their level of agreement for each proposition according to the Likert scale (1 strongly disagree 5:strongly agree) with the possibility to add comments. After each round, a facilitator modified the prepositions according to the comments received. The consensus for each preposition was considered achieved if the agreement was equal or more than 75% <h3>Results</h3> Three Delphi rounds were necessary in order to reach agreement. After the first round, 20 of the 93 definitions retrieved by the literature reached the consensus. During the second one, 23 propositions achieved the agreement while, after the last Delphi round, the number of propositions increased to 27. All the members responded to all the phases of the survey. Final definitions for US identification of CPPD are illustrated in Table 1 <h3>Conclusions</h3> To our knowledge this is the first set of definitions for US identification of CPPD created according to a consensus procedure between experts. These definitions should help sonographers to classify correctly patients with suspected CPPD thus giving the possibility to organise multicentre studies. However, the reliability and the diagnostic accuracy of this set has to be assessed before they become integral part of the daily clinical practice <h3>Disclosure of Interest</h3> None declared
SP0096 Optimization of MTX in RA Treatment
Authors: M. Schiff
Journal: Annals of the Rheumatic Diseases (2016)

EULAR and ACR guidelines agree that Methotrexate (MTX) should be the first part of Rheumatoid Arthritis therapy if there is no contraindication As stated in the EULAR guidelines "<i>MTX should be part of the first treatment strategy in patients with active RA…</i> and thus continues to serve as an anchor drug in RA." After decades of successful use of MTX the ideal way to optimize MTX is still being discussed. This presentation will address MTX as the current anchor drug in RA and how to better optimize its dosing for best patient care. Recent EULAR, ACR presentations will be highlighted. The pharmokinetics will be illustrated from recent Annals of Rheumatic disease papers to help clinicians optimize MTX. Genetic concerns will be addressed and how they might impact the clinical utility and future dosing of MTX. <h3>Selected references</h3> Ranganathan, P et al: Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003;62:4–9 Schiff MH: Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1892. doi: 10.1002/acr.22076. Schiff MH, Jaffe JS, Freundlich B: Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014 Aug;73(8):1549–51. doi: 10.1136/annrheumdis-2014-205228. Epub 2014 Apr 12. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al. Choosing wisely: the American College of Rheumatology9s top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken) 2013;65:329–39. Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, et al, for the MC-MTX.6/RH Study Group.Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73–81. Schiff MH et al: Oral to Subcutaneous Methotrexate. Dose Conversion Strategies in the Treatment of Rheumatoid Arthritis. Oral presentation: ACR 2015. Müller, R et al: Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum. 2015 Aug;45(1):28–34 DOI: http://dx.doi.org/10.1016/j.semarthrit.2015.02.009 <h3>Disclosure of Interest</h3> None declared
Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study
Authors: Hajo Grundmann, Corinna Glasner, Barbara Albiger, David M Aanensen, Chris T Tomlinson, Arjana Tambić Andrasević, Rafael Cantón, Yehuda Carmeli, Alexander W Friedrich, Christian G Giske, Youri Glupczynski, Marek Gniadkowski, David M Livermore, Patrice Nordmann, Laurent Poirel, Gian M Rossolini, Harald Seifert, Alkiviadis Vatopoulos, Timothy Walsh, Neil Woodford, Dominique L Monnet, Andi Koraqi, Denada Lacej, Petra Apfalter, Rainer Hartl, Youri Glupczynski, Te-Din Huang, Tanya Strateva, Yuliya Marteva-Proevska, Arjana Tambic Andrasevic, Iva Butic, Despo Pieridou-Bagatzouni, Panagiota Maikanti-Charalampous, Jaroslav Hrabak, Helena Zemlickova, Anette Hammerum, Lotte Jakobsen, Marina Ivanova, Anastasia Pavelkovich, Jari Jalava, Monica Österblad, Laurent Dortet, Sophie Vaux, Martin Kaase, Sören G. Gatermann, Alkiviadis Vatopoulos, Kyriaki Tryfinopoulou, Ákos Tóth, Laura Jánvári, Teck Wee Boo, Elaine McGrath, Yehuda Carmeli, Amos Adler, Annalisa Pantosti, Monica Monaco, Lul Raka, Arsim Kurti, Arta Balode, Mara Saule, Jolanta Miciuleviciene, Aiste Mierauskaite, Monique Perrin-Weniger, Paul Reichert, Nina Nestorova, Sonia Debattista, Gordana Mijovic, Milena Lopicic, Ørjan Samuelsen, Bjørg Haldorsen, Dorota Zabicka, Elzbieta Literacka, Manuela Caniça, Vera Manageiro, Ana Kaftandzieva, Elena Trajkovska-Dokic, Maria Damian, Brandusa Lixandru, Zora Jelesic, Anika Trudic, Milan Niks, Eva Schreterova, Mateja Pirs, Tjasa Cerar, Jesús Oteo, Belén Aracil, Christian Giske, Karin Sjöström, Deniz Gür, Asli Cakar, Neil Woodford, Katie Hopkins, Camilla Wiuff, Derek J. Brown
Journal: The Lancet Infectious Diseases (2016)